Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $243 | In Stock | |
5 mg | $793 | In Stock | |
10 mg | $1,230 | In Stock |
Description | Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis. |
Targets&IC50 | IL-23:10pM (kd,cynomolgus), IL-23:10pM (kd,human), IL-17:17 pM (cynomolgus), IL-17:2 pM (human) |
In vitro | With Kds <10 pM, Risankizumab (BI 655066) exhibits high affinity for human and cynomolgus IL23[3]. Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[2]. |
In vivo | In mice, Risankizumab (BI 655066) inhibits IL23-induced ear swelling and cytokine production following a single intraperitoneal (i.p.) dosage of 1 mg/kg[2]. |
Alias | Risankizumab rzaa, SKYRIZI, ABBV 066, BI-655066 |
Cas No. | 1612838-76-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.